Bladder Cancer Clinical Trial

Study to Determine Possible Effects of Apalutamide on EGFR Expression in Patients With Non-muscle Invasive Bladder Cancer

Summary

This phase I trial tests the molecular effects of apalutamide in patients with non-muscle invasive bladder cancer. Apalutamide is in a class of medications called androgen receptor inhibitors. It works by blocking the effects of androgen (a male reproductive hormone) to stop the growth and spread of tumor cells. Previous studies have suggested that expression of a protein called epidermal growth factor receptor (EGFR) on tumor cells is related to bladder cancer disease progression. This trial may help doctors evaluate if apalutamide has any effect on EGFR expression in patients with non-muscle invasive bladder cancer.

View Full Description

Full Description

PRIMARY OBJECTIVE:

I. To compare epidermal growth factor receptor (EGFR) messenger ribonucleic acid (mRNA) expression measured by reverse transcriptase polymerase chain reaction (rt-PCR) in normal appearing urothelium adjacent to tumor (measured as a ratio relative to urothelium and lamina-propria specific markers) in participants treated with apalutamide therapy versus (vs.) untreated participants.

SECONDARY OBJECTIVES:

I. To determine the possible effect of apalutamide on EGFR expression (by rtPCR) in the subgroup of patients whose normal appearing urothelium adjacent to tumor expresses the AR (at least "1" by immunohistochemistry [IHC] score).

II. To correlate AR expression in adjacent urothelium (by IHC score) with EGFR expression by rtPCR in treated and untreated participants.

III. Comparison of toxicity of treatment group to untreated control.

EXPLORATORY OBJECTIVES:

I. Comparison of AR and EGFR (and possibly phosphorylated EGFR [pEGFR]) staining levels (low, moderate, high; by immunocytology) in pre-treatment vs. post-treatment bladder wash cytology.

II. To compare expression of direct androgen response gene (ADAR)-2 measured by rtPCR in normal appearing adjacent (to tumor) urothelium that does and does not express AR (by IHC), in apalutamide treated participants and untreated controls.

III. Ki-67 expression (by IHC) in normal appearing urothelium adjacent to tumor in treated vs. untreated participants.

IV. Subgroup analysis of Ki-67 expression in the AR+ subgroup. V. Differences in expression of AR, EGFR, pEGFR, and Ki-67 (by semi-quantitative IHC) in tumor in treated vs untreated participants.

VI. Comparison of demographics of two groups. VII. Change in EGFR expression by rt-PCR in tumor from treated vs. untreated participants.

VIII. Morbidities of treatment (breast tenderness, sexual or urinary side effects, seizure(s), depression, abnormal liver function tests [LFTs]).

IX. Comparison of pre vs. post intervention urinary biomarkers (CxBladderTM) in both groups, examining the 5 RNAs (by rtPCR) that make up the test, both as a group and each RNA separately.

X. Fibroblast growth factor receptor 3 (FGFR3) mutation analysis in deoxyribonucleic acid (DNA) extracted from formalin fixed paraffin embedded (FFPE) blocks from neighboring normal urothelium and tumor tissue in treated vs. untreated participants.

XI. Define changes in the tumor immune microenvironment pre- and post-apalutamide through liquid biopsies of blood and urine using high-dimensional flow cytometry and single cell transcriptomics.

XII. Analyze tumor (biopsy specimen) infiltrating CD8+ T-cells by single RNA Sequencing (scRNA-seq) and high dimensional spectral flow cytometry to evaluate TCF1/Tcf7 transcript levels, and perform IHC of CD44+, CD62L, and SLAMF6.

XIII. Other exploratory markers.

OUTLINE: Patients are randomized to 1 of 2 arms.

ARM 1: Patients receive apalutamide orally (PO) once daily (QD) on days 1-21. Patients undergo TURBT on day 21. Up to 28 days of treatment is permitted in the absence of unacceptable toxicity. Patients undergo blood specimen collection at baseline and at time of TURBT.

ARM 2: Patients undergo TURBT on day 21. Patients undergo blood specimen collection at baseline and at time of TURBT.

After completion of study treatment, patients are followed up 20-30 days after TURBT.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Biologic male adults ( >= 18 years old)

Note: Because no dosing or adverse event (AE) data are currently available on the use of apalutamide in participants < 18 years of age, children are excluded from this study but will be eligible for future pediatric trials, if applicable.
Have suspected non-muscle invasive bladder carcinoma (NMIBC) on clinic-based cystoscopy or imaging as viewed by an American Urological Association (AUA) board-certified urologist

Have had cross sectional imaging of the abdomen and pelvis (computed tomography [CT] or magnetic resonance imaging [MRI] with or without contrast) within 6 months prior to enrollment with no signs of upper tract urothelial cancer (UC), invasive, nor metastatic disease

Note: If adenopathy or upper tract abnormalities are identified, a negative biopsy and or ureteroscopy is required prior to enrollment

Newly diagnosed or occasionally recurrent bladder cancer (BC)

Note: Occasional recurrence is defined as =< 2 prior NMIBC episodes in the 18 months preceding cystoscopy where the index tumor was identified
Participants with single and multiple tumor lesions
Eastern Cooperative Oncology Group (ECOG) performance status =< 1
Total bilirubin =< 1.5 x institutional upper limit of normal (note: in participants with Gilbert's syndrome, if total bilirubin is > 1.5 x upper limit of normal, measure direct and indirect bilirubin and if direct bilirubin is =< 1.5 x upper limit of normal, participants may be eligible)
Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) =< 2 × institutional upper limit of normal
Alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) =< 2 × institutional upper limit of normal
Urine Culture < 50,000 colonies/cc of 1 or more organisms (if found and treated and a confirmed negative culture obtained off antibiotics before study drug is started, they will be eligible)
Serum Testosterone >= 300 ng/dL
Thyroid stimulating hormone (TSH) within institutional normal
White blood cell count (WBC) =< 0.5 × institutional lower limit of normal
The effects of Apalutamide on the developing human fetus at the recommended therapeutic dose are unknown. For this reason, men who are having sex that can lead to pregnancy must use an acceptable form of contraception (vasectomy with the absence of sperm, sexual abstinence, condoms) throughout the course of the study
Ability to understand and the willingness to sign a written informed consent document

Exclusion Criteria:

Participants who have had a previous exposure to sex hormone (e.g., exogenous androgens) or anti-androgenic therapies (e.g., luteinizing hormone-releasing hormone [LHRH] agonists, LHRH antagonists, 5 alpha reductase-inhibitors, abiraterone or other anti-androgens) within 6 months of accrual
Participants who are taking the following medications that increase seizure risks: (e.g., clozapine, olanzapine, risperidone, ziprasidone),phenothiazine, antipsychotics (e.g., chlorpromazine, mesoridazine, thioridazine), bupropion, lithium, meperidine, pethidine, phenothiazine and tricyclic antidepressants (e.g., amitriptyline, desipramine, doxepin, imipramine, maprotiline),mirtazapine, selective serotonin reuptake inhibitors (e.g., escitalopram, citalopram, fluoxetine), serotonin norepinephrine reuptake inhibitors (e.g., venlafaxine, desvenlafaxine, levomilnacipran), stimulants (e.g., amphetamines, methylphenidate), monoamine oxidase inhibitors (e.g., phenelzine, selegiline)
Participants taking any form of anticoagulation (e.g., heparin, warfarin, lovenox, apixaban, rivaroxaban, dabigatran, edoxaban, betrixaban)
Concurrent use of drugs in category X drug interactions with apalutamide
Participants receiving any other investigational agents
History of allergic reactions attributed to compounds of similar chemical or biologic composition to apalutamide
History of prior or concurrent muscle invading UC, or concurrent prostatic urethral, urethral, or upper tract UC or non-urothelial bladder cancer
History of radiation therapy to the pelvis, prostate or prostatic bed, or rectum
Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements

Study is for people with:

Bladder Cancer

Phase:

Phase 1

Estimated Enrollment:

80

Study ID:

NCT05521698

Recruitment Status:

Not yet recruiting

Sponsor:

National Cancer Institute (NCI)

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 6 Locations for this study

See Locations Near You

University of Arizona Cancer Center - Prevention Research Clinic
Tucson Arizona, 85719, United States More Info
Juan Chipollini
Contact
520-694-4032
[email protected]
Juan Chipollini
Principal Investigator
Cedars Sinai Medical Center
Los Angeles California, 90048, United States More Info
Michael A. Ahdoot
Contact
310-423-2659
[email protected]
Michael A. Ahdoot
Principal Investigator
National Cancer Institute Urologic Oncology Branch
Bethesda Maryland, 20892, United States More Info
Sandeep Gurram
Contact
240-858-3700
[email protected]
Sandeep Gurram
Principal Investigator
University of Rochester
Rochester New York, 14642, United States More Info
Edward M. Messing
Contact
585-275-3345
[email protected]
Edward M. Messing
Principal Investigator
Ohio State University Comprehensive Cancer Center
Columbus Ohio, 43210, United States More Info
Debasish Sundi
Contact
219-713-9783
[email protected]
Debasish Sundi
Principal Investigator
University of Wisconsin Carbone Cancer Center - University Hospital
Madison Wisconsin, 53792, United States More Info
Kyle A. Richards
Contact
608-262-0759
[email protected]
Kyle A. Richards
Principal Investigator

How clear is this clinincal trial information?

Study is for people with:

Bladder Cancer

Phase:

Phase 1

Estimated Enrollment:

80

Study ID:

NCT05521698

Recruitment Status:

Not yet recruiting

Sponsor:


National Cancer Institute (NCI)

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.